News
- Author:
- Amy Karon
Publish date: February 12, 2019
The 8-week mindfulness course improved stress and depression in patients with inflammatory bowel disease.
News
- Author:
- Amy Karon
Publish date: February 6, 2019
But 13% of lesions classified as probably benign (LI-RADS2) were actually hepatocellular carcinomas.
News
- Author:
- Amy Karon
Publish date: February 5, 2019
Its prevalence rose nearly 700% between 2002 and 2017.
News
- Author:
- Amy Karon
Publish date: February 4, 2019
In all, 42% of initial responders maintained a histologic response.
News
- Author:
- Amy Karon
Publish date: February 1, 2019
It’s essential to determine whether the symptoms are caused by inflammation or another etiology that can be addressed separately.
News
- Author:
- Amy Karon
Publish date: February 1, 2019
Mesalamine and diazo-bonded 5-aminosalicylic acid are still the primary drugs recommended for treatment.
News
- Author:
- Amy Karon
Publish date: January 24, 2019
The drug cut relapse rates in select patients without causing symptomatic anemia.
News
- Author:
- Amy Karon
Publish date: January 15, 2019
Eight weeks after FMT, 32% of the donor group achieved steroid-free remission, compared with 9% of the autologous FMT group (odds ratio, 5; P
News
- Author:
- Amy Karon
Publish date: January 15, 2019
IFP has had a poor prognosis and long-term data on treatment options are needed.
News
- Author:
- Amy Karon
Publish date: January 14, 2019
Both platinum-etoposide and taxane therapies produced high response rates (71% each), but patients did not respond to checkpoint inhibitor therapy....
News
- Author:
- Amy Karon
Publish date: January 11, 2019
Median progression-free survival was 6.1 months for veliparib plus cisplatin-etoposide versus 5.5 months for placebo plus cisplatin-etoposide.
News
- Author:
- Amy Karon
Publish date: January 10, 2019
In all, 5.9% of adults with low-normal thyroid function had advanced liver fibrosis, compared with 2.8% of individuals with strict-normal thyroid f...
News
- Author:
- Amy Karon
Publish date: January 10, 2019
Adverse events led to dose delays or reductions in 95% of patients. Serious adverse events affected 15% of patients and in most cases led them to s...
News
- Author:
- Amy Karon
Publish date: January 9, 2019
The treatment was effective and well tolerated in patients who could not receive granulocyte colony-stimulating factor therapy.
News
- Author:
- Amy Karon
Publish date: January 9, 2019
A baseline C-reactive protein level more than three times above the upper limit of normal correlated significantly with 12-week etanercept response...
